Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation...

Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent
Radiation Oncology Conference
Conference Presentation Highlights Monte Carlo Dose Calculation Benefits in
Precision Radiation Delivery for Lung Cancer

SUNNYVALE, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Accuray Incorporated
(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today
that the company will showcase the treatment planning capabilities of the
CyberKnife(R) Robotic Radiosurgery System at the 10th Biennial European
Society for Therapeutic Radiology and Oncology (ESTRO) Conference on Physics
and Radiation Technology for Clinical Radiotherapy in Maastricht, The
Netherlands.

The latest generation of the MultiPlan(R) Treatment Planning System provides
the most comprehensive set of tools available for high-precision radiosurgery
treatment planning. The CyberKnife System's planning capabilities also include
Monte Carlo Dose Calculation, which produces results in minutes compared to
what commonly requires hours or days with other systems.

"We strongly believe that these new capabilities will transform the treatment
planning practice, specifically for the treatment of lung tumors," said
Frederic Sottilini, Senior Director, Marketing, Accuray EMEA.

Clinical findings will be presented during the conference, including the
results of a study presented by Erasmus MC-Daniel den Hoed Cancer Center that
demonstrates the benefits of the dose calculations performed using the
CyberKnife System's Monte Carlo Dose Calculation in the treatment of Non-Small
Cell Lung Cancer.

Additionally a Lunch Symposium will be held on Monday, August 31 at 1:00 p.m.
CET in room 04/05, where conference attendees can learn more about the
versatility and precision of the CyberKnife System's treatment planning and
delivery technologies.

"Medical physicists from renowned academic centers will contribute to the
scientific quality of this symposium, which should gather physicists from all
over Europe who are interested in learning more about the highly-sophisticated
treatment planning techniques that are available," said Sottilini.

About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body stabilization
frames.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global
leader in the field of radiosurgery dedicated to providing an improved quality
of life and a non-surgical treatment option for those diagnosed with cancer.
Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which
extends the benefits of radiosurgery to include extracranial tumors, including
those in the spine, lung, prostate, liver and pancreas. To date, the
CyberKnife System has been used to treat more than 70,000 patients worldwide
and currently 176 systems have been installed in leading hospitals in the
Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, as to performance of products,
clinical studies, and market acceptance are forward-looking statements within
the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements speak only as of the
date the statements are made and are based on information available at the
time those statements are made and/or management's good faith belief as of
that time with respect to future events. You should not put undue reliance on
any forward-looking statements. Important factors that could cause actual
performance and results to differ materially from the forward-looking
statements we make include: commercialization of products; market acceptance
of products; competing products; and other risks detailed from time to time
under the heading "Risk Factors" in our report on Form 10-K for the 2008
fiscal year, as updated from time to time by our quarterly reports on Form
10-Q and our other filings with the Securities and Exchange Commission. The
Company's actual results of operations may differ significantly from those
contemplated by such forward-looking statements as a result of these and other
factors. We assume no obligation to update forward-looking statements to
reflect actual performance or results, changes in assumptions or changes in
other factors affecting forward-looking information, except to the extent
required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Euan Thomson, Ph.D.
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Omar Dawood, M.D., MPH
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85068

SOURCE Accuray

Stephanie Tomei, Senior Manager, Public Relations, +1-408-789-4234,
stomei@accuray.com; or Sancie Nakarat, Manager, EU Marketing , +33 6 81 36 84
34, snakarat@accuray.com, both of Accuray Incorporated